5WK0 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Aligos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.73 |
| 52 Week High | US$25.50 |
| 52 Week Low | US$7.15 |
| Beta | 2.18 |
| 11 Month Change | 0% |
| 3 Month Change | 41.35% |
| 1 Year Change | -38.27% |
| 33 Year Change | -96.75% |
| 5 Year Change | n/a |
| Change since IPO | -97.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5WK0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 4.5% |
| 1Y | -38.3% | -16.4% | 13.5% |
Return vs Industry: 5WK0 underperformed the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: 5WK0 underperformed the German Market which returned 13.5% over the past year.
Price Volatility
| 5WK0 volatility | |
|---|---|
| 5WK0 Average Weekly Movement | 19.0% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5WK0's share price has been volatile over the past 3 months.
Volatility Over Time: 5WK0's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 68 | Larry Blatt | www.aligos.com |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
Aligos Therapeutics, Inc. Fundamentals Summary
| 5WK0 fundamental statistics | |
|---|---|
| Market cap | €44.39m |
| Earnings (TTM) | -€67.83m |
| Revenue (TTM) | €7.14m |
6.2x
P/S Ratio-0.7x
P/E RatioIs 5WK0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5WK0 income statement (TTM) | |
|---|---|
| Revenue | US$7.97m |
| Cost of Revenue | US$75.59m |
| Gross Profit | -US$67.62m |
| Other Expenses | US$8.11m |
| Earnings | -US$75.73m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.29 |
| Gross Margin | -848.76% |
| Net Profit Margin | -950.61% |
| Debt/Equity Ratio | 0% |
How did 5WK0 perform over the long term?
See historical performance and comparison